Quantum correlation and classical correlation dynamics in the spin-boson model

We study the quantum correlation and classical correlation dynamics in a spin-boson model. For two different forms of spectral density, we obtain analytical results and show that the evolutions of both correlations depend closely on the form of the initial state. At the end of evolution, all correlations initially stored in the spin system transfer to reservoirs. It is found that for a large family of initial states, quantum correlation remains equal to the classical correlation during the course of evolution. In addition, there is no increase in the correlations during the course of evolution.Comment: 10 pages, 5 figure

Synthesis of Esters of Ginsenoside Metabolite M1 and Their Cytotoxicity on MGC80-3 Cells

molecule

Baduanjin exercise for patients with breast cancer : A systematic review and meta-analysis

Peer reviewe

Flavonoid Ampelopsin Inhibits the Growth and Metastasis of Prostate Cancer In Vitro and in Mice

The objective of this study was to evaluate the chemopreventive effect of a novel flavonoid, ampelopsin (AMP) on the growth and metastasis of prostate cancer cells. AMP showed the more potent activity in inhibiting the proliferation of androgen-sensitive LNCaP and, to less extent, androgen-independent PC-3 human prostate cancer cell lines in vitro, primarily by induction of apoptosis associated with down-regulation of bcl-2. On the other hand, AMP showed much less activity in inhibiting the proliferation of normal prostate epithelial cells than that of prostate cancer cell lines. AMP also inhibited the migration and invasion of PC-3 cells in vitro associated with down-regulation of CXCR4 expression. In the animal study using an orthotopic prostate tumor model, AMP (150 and 300 mg/kg body weight) inhibited the growth of PC-3 tumors and lymph node and lung metastases in a dose-dependent manner. Compared to the control mice, mice treated with AMP at 300 mg/kg BW had reduced final tumor weight by 49.2% (P<0.05), lymph node metastases by 54.5% (P = 0.3) and lung metastases by 93% (P<0.05), but had no apparent alteration on food intake or body weight. The in vivo anti-growth and anti-metastasis activities of AMP were associated with induction of apoptosis and inhibition of proliferation of prostate cancer cells, reduction of prostate tumor angiogenesis, and reduction of CXCR4 expression. Our results provide supporting evidence to warrant further investigation to develop AMP as a novel efficacious and safe candidate agent against progression and metastasis of prostate cancer

Towards More Usable Dataset Search: From Query Characterization to Snippet Generation

Reusing published datasets on the Web is of great interest to researchers and developers. Their data needs may be met by submitting queries to a dataset search engine to retrieve relevant datasets. In this ongoing work towards developing a more usable dataset search engine, we characterize real data needs by annotating the semantics of 1,947 queries using a novel fine-grained scheme, to provide implications for enhancing dataset search. Based on the findings, we present a query-centered framework for dataset search, and explore the implementation of snippet generation and evaluate it with a preliminary user study.Comment: 4 pages, The 28th ACM International Conference on Information and Knowledge Management (CIKM 2019

Trifolirhizin mitigates ovalbumin-induced lung inflammation and tissue damage in neonatal rats via inhibition of the NF-κB signaling pathway

Purpose: To investigate the effect of trifolirhizin on neonatal rat model of asthma, and the mechanism of action involved. Methods: Neonatal rats (n = 50) were randomly assigned to 5 groups (10 pups/group): sham, asthma and three treatment groups. With the exception of sham group, the rat pups were sensitized intraperitoneally with ovalbumin (OVA) at a dose of 20 µg/kg on days 7 and 21 postpartum. Rats in the treatment groups received trifolirhizin intragastrically at doses of 2, 4 and 5 mg/kg on day 7 postpartum. Eosinophils in bronchoalveolar lavage fluid (BALF) were counted using hematological analyzer. Serum immunoglobulin (Ig)E and interleukin (IL)-4, IL-5 and IL-13 levels in BALF were determined using their respective enzyme-linked immunosorbent assay (ELISA) kits. Messenger RNA (mRNA) expressions of mucin 5AC (Muc5AC), mucin 5B (Muc5B), tumor necrosis factor α (TNF-α) and intercellular adhesion molecule-1 (ICAM-1) were determined using immunohistochemical staining, while the protein expression of inhibitor of nuclear factor of kappa light polypeptide gene enhancer in B-cells alpha (IκBα) was assayed by Western blotting. Results: Serum IgE level was significantly higher in asthma group than in sham group, but was significantly and dose-dependently reduced after treatment with trifolirhizin (p &lt; 0.05). Lung tissue damage was also significantly mitigated in the treatment groups, relative to asthma group (p &lt; 0.05). Trifolirhizin treatment significantly and dose-dependently downregulated the mRNA expressions of Muc5AC, Muc5B, TNF-α and ICAM-1, but upregulated IκBα protein expression significantly and dosedependently (p &lt; 0.05). Bronchoalveolar lavage fluid (BALF) levels of IL-4, IL-5 and IL-13 were significantly higher in asthma group, but were significantly and dose-dependently reduced after treatment with trifolirhizin (p &lt; 0.05). Conclusion: These results indicate that trifolirhizin mitigates OVA-induced lung inflammation and tissue damage in neonatal rats via inhibition of NF-κB signaling pathway, thus affording a potential therapeutic strategy for the management of asthma&nbsp

Comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B: A Systematic Review

Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as tenofovir and adefovir, are recommended for treatment of patients with chronic hepatitis B. tenofovir is a nucleoside analog with selective activity against hepatitis b virus and has been shown to be more potent in vitro than adefovir. But the results of trials comparing tenofovir and adefovir in the treatment of chronic hepatitis B were inconsistent. However, there was no systematic review on the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B. To evaluate the comparison of the efficacy of tenofovir and adefovir in the treatment of chronic hepatitis B we conducted a systematic review and meta-analysis of clinical trials. We searched PUBMED, Web of Science, EMBASE, CNKI, VIP database, WANFANG database, the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. Finally six studies were left for analysis which involved 910 patients in total, of whom 576 were included in tenofovir groups and 334 were included in adefovir groups. At the end of 48-week treatment, tenofovir was superior to adefovir at the HBV-DNA suppression in patients[RR = 2.59; 95%CI(1.01-6.67), P = 0.05]. While there was no significant difference in the ALT normalization[RR = 1.15; 95%CI(0.96-1.37), P = 0.14], HBeAg seroconversion[RR = 1.32; 95%CI(1.00-1.75), P = 0.05] and HBsAg loss rate[RR = 1.19; 95%CI(0.74-1.91), P = 0.48]. More high-quality, well-designed, randomized controlled, multi-center trails are clearly needed to guide evolving standards of care for chronic hepatitis B